Medidata to Offer DCT Platform
Medidata, a Dassault Systèmes company, has announced the launch of the Medidata Decentralized Clinical Trials (DCT) Program, a comprehensive set of unified, secure technologies that enable full decentralization across the clinical trial continuum. Drug, vaccine, and medical device developers (sponsors) and contract research organizations (CROs) can take advantage of the platform offering on the market which combines:
- Technology and workflows to virtualize patient participation
- Tools that facilitate sponsor oversight of patient safety and data quality
- Direct-to-patient services, including facilitation of delivery of study drugs to the home
To date, Medidata has applied its decentralizing technologies across more than 44,000 clinical sites around the world in multiple languages involving more than 600,000 patients with a wide array of illnesses.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
